Clinical applications of cardiovascular angiogenesis. J Card Surg 2001;16(6):490-7
Date
04/02/2002Pubmed ID
11925031DOI
10.1111/j.1540-8191.2001.tb00555.xScopus ID
2-s2.0-0035573438 (requires institutional sign-in at Scopus site) 8 CitationsAbstract
Angiogenesis is fundamental to both normal physiologic (wound healing) and pathologic (cancer) processes. Manipulation of divergent angiogenic signals promises effective therapy of atherosclerotic cardiovascular disease. Positive proangiogenic strategies promise collateral circulation to ischemic territories, while negative antiangiogenic strategies starve the fibromuscular proliferation within the atherosclerotic lesion. Indeed, recent phase 1 trials suggest that delivering DNA or recombinant protein to the site of vascular occlusion may stimulate physiologically significant collateral circulation in chronically ischemic myocardium. While symptomatic and functional improvement has been documented, toxicity profiles and effects on long-term patient survival are still unclear. The purposes of this article are as follows: (1) to review the pathophysiologic basis for pro- and antiangiogenic strategies in the treatment of cardiovascular disease, (2) to examine the clinical trials of proangiogenic gene or recombinant protein delivery into ischemic beds, and conversely, (3) to explore antiangiogenic strategies in the prevention and treatment of intimal neovascularization and smooth muscle proliferation within the vessel wall.
Author List
Zimmerman MA, Selzman CH, Raeburn CD, Calkins CM, Barsness K, Harken AHAuthor
Casey Matthew Calkins MD Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Cardiovascular SystemClinical Trials as Topic
Coronary Artery Disease
Endothelial Growth Factors
Humans
Lymphokines
Neovascularization, Pathologic
Neovascularization, Physiologic
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
